AI assistant
Alset Inc. — Director's Dealing 2025
Apr 3, 2025
34175_dirs_2025-04-02_755bb540-baf5-4db1-beca-13bcce6d6f6c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMPACT BIOMEDICAL INC. (IBO)
CIK: 0001834105
Period of Report: 2025-03-31
Reporting Person: Chan Heng Fai Ambrose (Director, 10% Owner)
Reporting Person: Alset International Ltd (10% Owner)
Reporting Person: Alset Inc. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-31 | Common Stock | S | 300000 | $1.028 | Disposed | 1253904 | Indirect |
| 2025-04-01 | Common stock | S | 400000 | $0.982 | Disposed | 853904 | Indirect |
| 2025-04-01 | Common Stock | S | 650000 | $1.447 | Disposed | 1910976 | Indirect |
| 2025-04-01 | Common Stock | S | 1176918 | $1.08 | Disposed | 734058 | Indirect |
Footnotes
F1: On March 31, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $1.028. This transaction was executed in multiple trades at prices ranging from $0.82 to $1.29. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2: On April 1, 2025, Alset International Limited sold 400,000 shares of the Issuer's common stock at a weighted average sale price of $0.9816. This transaction was executed in multiple trades at prices ranging from $0.6938 to $1.36. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: On April 1, 2025, Alset Inc. sold 650,000 shares of the Issuer's common stock at a weighted average sale price of $1.447. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4: On April 1, 2025, Alset Inc. sold 1,176,918 shares of the Issuer's common stock at a weighted average sale price of $1.08. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5: Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc.